These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 1705823

  • 21. Pancreastatin inhibits insulin secretion as induced by glucagon, vasoactive intestinal peptide, gastric inhibitory peptide, and 8-cholecystokinin in the perfused rat pancreas.
    Peiró E, Miralles P, Silvestre RA, Villanueva ML, Marco J.
    Metabolism; 1989 Jul; 38(7):679-82. PubMed ID: 2661967
    [Abstract] [Full Text] [Related]

  • 22. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas.
    Göke R, Wagner B, Fehmann HC, Göke B.
    Res Exp Med (Berl); 1993 Jul; 193(2):97-103. PubMed ID: 8516568
    [Abstract] [Full Text] [Related]

  • 23. Effect of glucagon-like peptide-1 on insulin secretion.
    Shima K, Hirota M, Ohboshi C.
    Regul Pept; 1988 Aug; 22(3):245-52. PubMed ID: 3051138
    [Abstract] [Full Text] [Related]

  • 24. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion.
    Jia X, Brown JC, Ma P, Pederson RA, McIntosh CH.
    Am J Physiol; 1995 Apr; 268(4 Pt 1):E645-51. PubMed ID: 7733263
    [Abstract] [Full Text] [Related]

  • 25. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [Abstract] [Full Text] [Related]

  • 26. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG, Pittner R, Jodka C, Smith P, Young A.
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [Abstract] [Full Text] [Related]

  • 27. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [Abstract] [Full Text] [Related]

  • 28. Cholecystokinin-33 potentiates and vasoactive intestinal polypeptide inhibits gastric inhibitory polypeptide--induced insulin secretion in the perfused rat pancreas.
    Sandberg E, Ahrén B, Tendler D, Efendic S.
    Acta Endocrinol (Copenh); 1988 Apr; 117(4):545-51. PubMed ID: 3291528
    [Abstract] [Full Text] [Related]

  • 29. The enteroinsular axis in dipeptidyl peptidase IV-negative rats.
    Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CH.
    Metabolism; 1996 Nov; 45(11):1335-41. PubMed ID: 8931636
    [Abstract] [Full Text] [Related]

  • 30. GLP-1(7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action.
    Fridolf T, Ahrén B.
    Diabetes Res; 1991 Apr; 16(4):185-91. PubMed ID: 1802486
    [Abstract] [Full Text] [Related]

  • 31. Amylin (islet amyloid polypeptide) inhibition of insulin release in the perfused rat pancreas: implication of the adenylate cyclase/cAMP system.
    Silvestre RA, Salas M, García-Hermida O, Fontela T, Dégano P, Marco J.
    Regul Pept; 1994 Feb 24; 50(2):193-9. PubMed ID: 7514801
    [Abstract] [Full Text] [Related]

  • 32. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.
    J Clin Endocrinol Metab; 2003 Oct 24; 88(10):4897-903. PubMed ID: 14557471
    [Abstract] [Full Text] [Related]

  • 33. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug 24; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B, Hughes TE.
    Endocrinology; 2005 Apr 24; 146(4):2055-9. PubMed ID: 15604213
    [Abstract] [Full Text] [Related]

  • 35. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.
    Diabetologia; 2003 Feb 24; 46(2):222-30. PubMed ID: 12627321
    [Abstract] [Full Text] [Related]

  • 36. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism.
    Ding WG, Renström E, Rorsman P, Buschard K, Gromada J.
    Diabetes; 1997 May 24; 46(5):792-800. PubMed ID: 9133546
    [Abstract] [Full Text] [Related]

  • 37. Comparison of the insulinotropic activity of glucagon-superfamily peptides in rat pancreas perfusion.
    Suzuki S, Kawai K, Ohashi S, Watanabe Y, Yamashita K.
    Horm Metab Res; 1992 Oct 24; 24(10):458-61. PubMed ID: 1464409
    [Abstract] [Full Text] [Related]

  • 38. Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas.
    Inoue K, Hisatomi A, Umeda F, Nawata H.
    Horm Metab Res; 1991 Sep 24; 23(9):407-9. PubMed ID: 1743611
    [Abstract] [Full Text] [Related]

  • 39. The cyclic AMP-protein kinase A pathway restrains islet phospholipase A(2) activation.
    Simonsson E, Karlsson S, Ahrén B.
    Biochem Biophys Res Commun; 2000 Mar 05; 269(1):242-6. PubMed ID: 10694507
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun 05; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.